Gilead Science’s new chairman and chief executive officer outlined a growth plan this week at the J.P. Morgan Healthcare Conference in San Francisco, California.
Gilead Sciences outlined a growth plan this week at the J.P. Morgan Healthcare Conference in San Francisco, California, that calls for building on its existing portfolio of products, managing product expirations, and expanding further into the oncology space, particularly for immunotherapy agents.
The presentation Monday was an opportunity for new Chairman and Chief Executive Officer Dan O’Day to provide an update on the strategy he has developed since taking the helm 10 months ago.
Gilead’s clinical product pipeline includes multiple products for inflammatory diseases, fibrotic diseases, and oncology. “We’re focusing on the manipulation of the immune system to fight diseases,” he said.
One of the near-term drugs in this category is filgotinib (GLPG0634), a selective Janus kinase (JAK) inhibitor aimed at moderate-to-severe rheumatoid arthritis. Filgotinib was developed by Galapagos NV, which Gilead partnered with in July 2019. Gilead is seeking approvals for this agent in the United States, Europe, and Japan.
The drug is also being studied in ulcerative colitis and Crohn disease.
Gilead also has a robust pipeline in oncology products, with the furthest along being the CAR T-cell therapy KTE-X19 for relapsed refractory mantle cell lymphoma (MCL). The company is planning a biologics license application to the FDA.
Gilead has achieved impressive growth statistics in the HIV/AIDS drug market. The company has launched 15 antiviral products over the past decade, with a compound annual growth rate since 2011 for HIV products of 14%.
O’Day said he was optimistic about this year’s patent expiry of the emtricitabine-tenofovir combination Truvada, a pre-exposure prophylaxis (PrEP) for HIV/AIDS. Gilead aims to have 90% to 95% of patients under treatment with Truvada switched over to its newer F/TAF-based regimens, which include PrEP formulation emtricitabine/tenofovir disoproxil fumarate (Descovy), by the fourth quarter of this year.
Forty percent to 45% of individuals on PrEP for prevention are expected to be switched over to Descovy by the fourth quarter of 2020.
A source of confidence in these predictions, O’Day said, is that 8 of 10 individuals with HIV/AIDS are on Gilead agents currently, and the company has some leading products, such as Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide), an all-in-1 HIV-1 treatment that can be initiated in patients with little delay, has 0 cases of treatment-emergent resistance so far, and is the top-selling prescribed HIV regimen, he said. “It’s been growing 80% quarter on quarter since its launch.”
The drug, approved for use in the United States in 2018, passed the $1 billion sales mark 3 months ago.
Descovy was launched a few months ago and already, O’Day said, 20% of HIV at risk individuals are on PrEP today and 25% of PrEP scripts are for this product.
Gilead also has a capsid inhibitor moving into phase 2/3 trials that offers potential for less-frequent dosing for patients with HIV. “We’ve shown that we may be able to get up to twice-a-year infused doses and less-frequent oral doses for this,” O’Day said.
Eye on Pharma: Bevacizumab Update; Samsung Bioepis, J&J Settlement; Another EU Trastuzumab
December 6th 2023Outlook Therapeutics provides an update on the development of its bevacizumab candidate for age-related macular degeneration; Samsung Bioepis settles with Johnson & Johnson (J&J) over its ustekinumab biosimilar candidate; and the European Union gains another trastuzumab biosimilar.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
CVS Caremark Switches Up Biosimilar Coverage in 2024
November 27th 2023As new biosimilars are added to CVS Caremark’s standard formulary, others are removed. One notable change is with the Humira biosimilars: the pharmacy benefit manager has removed Amjevita in favor of Hyrimoz and an unbranded biosimilar.
Biosimilars Business Roundup For August 2023—Podcast Edition
September 5th 2023On this episode, we’re giving an overview of some of the biggest stories in the business space regarding biosimilars, like the approval of the first neurology biosimilar, growth projections from company quarterly expense reports, and some analyses about the health of the market.
Panelists Deliberate Strategies to Enhance Biosimilar Integration in Managed Care Spaces
November 13th 2023At the recent Academy of Managed Care Pharmacy Nexus meeting, panelists discussed the impact of introducing biosimilars in new medical fields, emphasizing the need for more education and collaboration to ensure their smooth integration into health care systems.